Exelixis Inc
NASDAQ:EXEL

Watchlist Manager
Exelixis Inc Logo
Exelixis Inc
NASDAQ:EXEL
Watchlist
Price: 34.83 USD 0.52% Market Closed
Market Cap: 9.9B USD
Have any thoughts about
Exelixis Inc?
Write Note

Wall Street
Price Targets

EXEL Price Targets Summary
Exelixis Inc

Wall Street analysts forecast EXEL stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EXEL is 33.32 USD with a low forecast of 23.23 USD and a high forecast of 40.95 USD.

Lowest
Price Target
23.23 USD
33% Downside
Average
Price Target
33.32 USD
4% Downside
Highest
Price Target
40.95 USD
18% Upside

EXEL Last Price Targets
Exelixis Inc

The latest public price target was made on Oct 30, 2024 by Joseph Catanzaro from Piper Sandler , who expects EXEL stock to rise by 3% over the next 12 months. You can read more about this price target by viewing the article on TheFly.

Analyst Price Target Date Article
Joseph Catanzaro
Piper Sandler
36 USD
Upside 3%
3 weeks ago
Oct 30, 2024
Exelixis price target raised to $36 from $33 at Piper Sandler
TheFly
David Lebowitz
Citigroup
38 USD
Upside 9%
3 weeks ago
Oct 30, 2024
Exelixis (EXEL) PT Raised to $38 at Citi
StreetInsider
Etzer Darout
BMO Capital
36 USD
Upside 3%
3 weeks ago
Oct 30, 2024
Exelixis (EXEL) PT Raised to $36 at BMO Capital
StreetInsider
Asthika Goonewardene
Truist Financial
38 USD
Upside 9%
3 weeks ago
Oct 30, 2024
Exelixis price target raised to $38 from $33 at Truist
TheFly
Kennen MacKay
RBC Capital
34 USD
Downside 2%
1 month ago
Oct 16, 2024
Exelixis (EXEL) PT Raised to $34 at RBC Capital
StreetInsider
Christopher Liu
Leerink Partners
28.5 USD
Downside 18%
1 month ago
Oct 16, 2024
Leerink Partners Reiterates Market Perform Rating on Exelixis (EXEL)
StreetInsider
Chris Shibutani
Goldman Sachs
18 USD
Downside 48%
1 month ago
Oct 16, 2024
Goldman Sachs Reiterates Sell Rating on Exelixis (EXEL)
StreetInsider
Akash Tewari
Jefferies
33 USD
Downside 5%
1 month ago
Oct 15, 2024
Exelixis price target raised to $33 from $30 at Jefferies
TheFly
Jeffrey Hung
Morgan Stanley
30 USD
Downside 14%
1 month ago
Oct 15, 2024
Morgan Stanley Out Mixed on Exelixis (EXEL), PT Raised to $30, 'ruling is short of a home run scenario'
StreetInsider
Asthika Goonewardene
Truist Financial
33 USD
Downside 5%
1 month ago
Oct 14, 2024
Truist Securities Reiterates Buy Rating on Exelixis (EXEL)
StreetInsider
Sudan Loganathan
Stephens
23 USD
Downside 34%
1 month ago
Oct 14, 2024
Stephens Reiterates Equal Weight Rating on Exelixis (EXEL)
StreetInsider
Jeffrey Hung
Morgan Stanley
28 USD
Downside 20%
1 month ago
Oct 11, 2024
Exelixis price target raised to $28 from $26 at Morgan Stanley
TheFly
Ashwani Verma
UBS
30 USD
Downside 14%
2 months ago
Sep 19, 2024
Exelixis initiated with a Neutral at UBS
TheFly
David Lebowitz
Citigroup
31 USD
Downside 11%
2 months ago
Sep 16, 2024
Citi Reiterates Buy Rating on Exelixis (EXEL)
StreetInsider
Jason Gerberry
Bank of America Securities
30 USD
Downside 14%
2 months ago
Sep 4, 2024
Exelixis (EXEL) PT Raised to $30 at BofA Securities
StreetInsider
Robert Burns
H.C. Wainwright
29 USD
Downside 17%
3 months ago
Aug 8, 2024
Exelixis (EXEL) PT Raised to $29 at H.C. Wainwright
StreetInsider
Silvan Tuerkcan
JMP Securities
29 USD
Downside 17%
3 months ago
Aug 7, 2024
Exelixis price target raised to $29 from $27 at JMP Securities
TheFly
David Lebowitz
New Street
31 USD
Downside 11%
6 months ago
May 20, 2024
Citi Reiterates Buy Rating on Exelixis (EXEL)
StreetInsider
George Farmertzer Darout
BMO Capital
29 USD
Downside 17%
6 months ago
May 20, 2024
BMO Capital Reiterates Outperform Rating on Exelixis (EXEL)
StreetInsider
Peter Lawson
Barclays
25 USD
Downside 28%
7 months ago
Apr 11, 2024
Barclays Downgrades Exelixis (EXEL) to Equalweight
StreetInsider
Show More Price Targets
Show Less Price Targets
Joseph Catanzaro
Piper Sandler
Price Target 36 USD
Upside/Downside 3%
View Source
David Lebowitz
Citigroup
Price Target 38 USD
Upside/Downside 9%
View Source
Etzer Darout
BMO Capital
Price Target 36 USD
Upside/Downside 3%
View Source
Asthika Goonewardene
Truist Financial
Price Target 38 USD
Upside/Downside 9%
View Source
Kennen MacKay
RBC Capital
Price Target 34 USD
Upside/Downside 2%
View Source
Christopher Liu
Leerink Partners
Price Target 28.5 USD
Upside/Downside 18%
View Source
Chris Shibutani
Goldman Sachs
Price Target 18 USD
Upside/Downside 48%
View Source
Akash Tewari
Jefferies
Price Target 33 USD
Upside/Downside 5%
View Source
Jeffrey Hung
Morgan Stanley
Price Target 30 USD
Upside/Downside 14%
View Source
Asthika Goonewardene
Truist Financial
Price Target 33 USD
Upside/Downside 5%
View Source
Sudan Loganathan
Stephens
Price Target 23 USD
Upside/Downside 34%
View Source
Jeffrey Hung
Morgan Stanley
Price Target 28 USD
Upside/Downside 20%
View Source
Ashwani Verma
UBS
Price Target 30 USD
Upside/Downside 14%
View Source
David Lebowitz
Citigroup
Price Target 31 USD
Upside/Downside 11%
View Source
Jason Gerberry
Bank of America Securities
Price Target 30 USD
Upside/Downside 14%
View Source
Robert Burns
H.C. Wainwright
Price Target 29 USD
Upside/Downside 17%
View Source
Silvan Tuerkcan
JMP Securities
Price Target 29 USD
Upside/Downside 17%
View Source
David Lebowitz
New Street
Price Target 31 USD
Upside/Downside 11%
View Source
George Farmertzer Darout
BMO Capital
Price Target 29 USD
Upside/Downside 17%
View Source
Peter Lawson
Barclays
Price Target 25 USD
Upside/Downside 28%
View Source
Show More Price Targets
Show Less Price Targets
Exelixis Inc Competitors:
Price Targets
ALKS
Alkermes Plc
25% Upside
ASND
Ascendis Pharma A/S
61% Upside
BCYC
Bicycle Therapeutics PLC
91% Upside
300601
Shenzhen Kangtai Biological Products Co Ltd
21% Upside
COYA
Coya Therapeutics Inc
162% Upside
MNKD
MannKind Corp
32% Upside
301207
Hualan Biological Bacterin Inc
56% Upside
INO
Inovio Pharmaceuticals Inc
168% Upside

Revenue
Forecast

Revenue Estimate
Exelixis Inc

For the last 8 years the compound annual growth rate for Exelixis Inc's revenue is 63%. The projected CAGR for the next 3 years is 11%.

63%
Past Growth
11%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Exelixis Inc

The compound annual growth rate of Exelixis Inc's operating income for the next 3 years is 57%.

N/A
Past Growth
57%
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
Exelixis Inc

The compound annual growth rate of Exelixis Inc's net income for the next 3 years is 46%.

N/A
Past Growth
46%
Estimated Growth
Estimates Accuracy
18%
Average Beat

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EXEL's stock price target?
Price Target
33.32 USD

According to Wall Street analysts, the average 1-year price target for EXEL is 33.32 USD with a low forecast of 23.23 USD and a high forecast of 40.95 USD.

What is Exelixis Inc's Revenue forecast?
Projected CAGR
11%

For the last 8 years the compound annual growth rate for Exelixis Inc's revenue is 63%. The projected CAGR for the next 3 years is 11%.

What is Exelixis Inc's Operating Income forecast?
Projected CAGR
57%

The compound annual growth rate of Exelixis Inc's operating income for the next 3 years is 57%.

What is Exelixis Inc's Net Income forecast?
Projected CAGR
46%

The compound annual growth rate of Exelixis Inc's net income for the next 3 years is 46%.

Back to Top